This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Circulation: Arrhythmia and Electrophysiology, Ahead of Print. BACKGROUND:There is no specific treatment for sudden cardiacarrest (SCA) manifesting as pulseless electric activity (PEA) and survival rates are low; unlike ventricular fibrillation (VF), which is treatable by defibrillation.
Circulation: Arrhythmia and Electrophysiology, Ahead of Print. Although there is consensus on the management of patients with Brugada Syndrome with high risk for sudden cardiacarrest, asymptomatic or intermediate-risk patients present clinical management challenges.
Photo by Cedars-Sinai milla1cf Fri, 03/01/2024 - 08:25 March 1, 2024 — Two new studies by Cedars-Sinai investigators support using artificial intelligence (AI) to predict sudden cardiacarrest-a health emergency that in 90% of cases leads to death within minutes.
If cardiacarrest from hypokalemia is imminent (i.e., mEq of K pushed fast and circulated theoretically would raise serum K immediately by 1.0 As I indicated above, in our cardiacarrest case, after pushing 40 mEq, the K only went up to 4.2 mEq/L, and 10 mEq would increase it by 3.3 mEq/L, from 1.9 mg/dL [1.03 0.16
But the full cohort of the CABANA trial did not show a significant reduction in the primary composite end point of death, disabling stroke, serious bleeding or cardiacarrest [7]. Circulation. Circulation. EAST-AFNET 4 trial had 2789 patients with early atrial fibrillation and cardiovascular conditions [8]. N Engl J Med.
She has not yet been seen by electrophysiology or had further genetic testing for Brugada syndrome. Circulation, 117, 1890–1893. [3]: As for our patient, on discharge, her EKG had completed returned to her baseline morphology and she has been doing well in follow-up. Heart Rhythm, 13(7): 1515-1520. [2]:
She has not yet been seen by electrophysiology or had further genetic testing for Brugada syndrome. Circulation, 117, 1890–1893. [3]: As for our patient, on discharge, her EKG had completed returned to her baseline morphology and she has been doing well in follow-up. Heart Rhythm, 13(7): 1515-1520. [2]:
Circulation: Arrhythmia and Electrophysiology, Ahead of Print. BACKGROUND:Sudden cardiac death is the most common cause of death in childhood hypertrophic cardiomyopathy (HCM). Recently, 2 risk scores have been developed to estimate the 5-year risk of sudden cardiac death. males), with a mean follow-up of 8.65.5
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content